Marksans Pharma gets EIR from USFDA; stock ends 4% higher

The company said that it received the Establishment Inspection Report from the USFDA in respect of inspection of the company's Goa facility carried out from February 25 to March 6, 2019.

Jun 06, 2019 04:06 IST India Infoline News Service

Marksans Pharma
Marksans Pharma said it received Establishment Inspection Report (EIR) from the USFDA in respect of inspection of the company's Goa facility carried out from February 25 to March 6, 2019.

Marksans Pharma Ltd ended at Rs22.70, up by Rs0.85 or 3.89% from its previous closing of Rs21.85 on the BSE. The scrip opened at Rs21.95 and touched a high and low of Rs23.05 and Rs21.65 respectively.

The BSE group 'B' stock of face value Rs1 touched a 52 week high of Rs40.55 on 04-Sep-2018 and a 52 week low of Rs20.95 on 14-May-2019. Last one week high and low of the scrip stood at Rs26.85 and Rs21.75 respectively.

Related Story